Guardant Health, Inc.
GH
Rank in Stocks
#1081
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Share Price
$159.93
Last synced: 2026-10-19
Market Cap
$21.46B
Change (1 day)
0.84%
Change (1 year)
127.83%
Country
US
Trade Guardant Health, Inc. (GH)
Category
Healthcare
Revenue for Guardant Health, Inc. (GH)
Revenue in Jun 2026 TTM: $1.18B
According to Guardant Health, Inc. latest financial reports the company's current revenue (TTM) is $1.18B. In 2023 the company made a revenue of $563.95M an increase over the revenue in the year 2022 that was $449.54M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Guardant Health, Inc. from 2016 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $1.18B | 60.09% |
| 2024 | $739.02M | 31.04% |
| 2023 | $563.95M | 25.45% |
| 2022 | $449.54M | 20.31% |
| 2021 | $373.65M | 30.32% |
| 2020 | $286.73M | 33.75% |
| 2019 | $214.38M | 136.52% |
| 2018 | $90.64M | 81.85% |
| 2017 | $49.84M | 97.40% |
| 2016 | $25.25M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $46.34B | 3,816.47% |
US
|
|
| $25.11B | 2,022.13% |
US
|
|
| $2.71B | 128.81% |
US
|
|
| - | - |
CN
|
|
| $7.37B | 523.11% |
US
|
